Chinese insurance and medical aesthetics sectors report divergent mid-year results

Major Chinese listed insurance companies reported diverse mid-year financial results for 2026, with net profit growth rates varying by as much as 20 times among top players. China Life Insurance led the group with a 228.6% increase in net profit, while China Taiping saw a 92% rise. In contrast, China Pacific Insurance recorded a growth rate of only 10.4%. This disparity is largely attributed to investment strategies and the shift toward dividend-paying insurance products as interest rates decline.

Simultaneously, the medical aesthetics upstream sector is facing significant profit pressure. Leading companies, including Haohai Biological Technology, Jinbo Bio, and Bloomage Biotech, have reported declining net profits or compressed margins. This downturn is driven by intense price competition for hyaluronic acid and recombinant collagen, increased depreciation costs from recent capacity expansions, and rising costs for digital marketing and live-streaming traffic.

While insurance companies are attempting to mitigate low interest rates by increasing equity asset allocations through a ‘dumbbell strategy,’ the medical aesthetics industry is struggling with a transition from high-growth scarcity to a more competitive, manufacturing-oriented market environment.